Supersolubilization and Amorphization of a Model Basic Drug, Haloperidol, by Interaction with Weak Acids

Purpose To present a novel approach of greatly enhancing aqueous solubility of a model weakly basic drug, haloperidol, by using weak acids that would not form salts with the drug and to attain physically stable form of amorphous drug by drying such aqueous solutions. Method Aqueous solubility of hal...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmaceutical research 2013-06, Vol.30 (6), p.1561-1573
Hauptverfasser: Singh, Saumya, Parikh, Tapan, Sandhu, Harpreet K., Shah, Navnit H., Malick, A. Waseem, Singhal, Dharmendra, Serajuddin, Abu T. M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1573
container_issue 6
container_start_page 1561
container_title Pharmaceutical research
container_volume 30
creator Singh, Saumya
Parikh, Tapan
Sandhu, Harpreet K.
Shah, Navnit H.
Malick, A. Waseem
Singhal, Dharmendra
Serajuddin, Abu T. M.
description Purpose To present a novel approach of greatly enhancing aqueous solubility of a model weakly basic drug, haloperidol, by using weak acids that would not form salts with the drug and to attain physically stable form of amorphous drug by drying such aqueous solutions. Method Aqueous solubility of haloperidol in presence of increasing concentrations of four different weak organic acids (malic, tartaric, citric, fumaric) were determined. Several concentrated aqueous solutions with differing drug-to-acid molar ratios were dried in vacuum oven, and dried materials were characterized by DSC, powder XRD, dissolution testing, and stability study. Result Acids were selected such that they would not form salts with haloperidol. Haloperidol solubility increased greatly with increased concentrations of malic, tartaric and citric acids, reaching >300 mg/g of solution. In contrast to the haloperidol HCl aqueous solubility of 4 mg/g, this may be called supersolubilization. Fumaric acid did not cause such solubilization as it had low water solubility. Dried solids formed dispersions of amorphous haloperidol in acids that were either amorphous or partially crystalline. Amorphous haloperidol was physically stable and had better dissolution rate than HCl salt. Conclusion A novel method of drug solubilization in aqueous media by acid–base interaction is presented. Physically stable amorphous systems of drugs may also be prepared by using this organic solvent-free approach.
doi_str_mv 10.1007/s11095-013-0994-7
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1349704744</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2983909201</sourcerecordid><originalsourceid>FETCH-LOGICAL-c402t-d73ff3bdab8bab2b7d37b4da017e94a55ec18fb83608abc35196752b25f41aaa3</originalsourceid><addsrcrecordid>eNp1kU9v1DAQxS1ERZfCB-CCLCEkDg2MYzuOj0uBtlIRB0Bwi8Z_0nXxxls7ESqfnmx3WxASp5Fmfm_maR4hzxi8ZgDqTWEMtKyA8Qq0FpV6QBZMKl5pEN8fkgWoWlStEuyQPC7lCgBapsUjclhzwUG0ckFWn6eNzyXFyYQYfuEY0kBxcHS5TnmzuuukniL9mJyP9C2WYOm7PF0e0zOMaZYHl-IxNTf0fBh9Rnsr-RnGFf3m8Qdd2uDKE3LQYyz-6b4eka8f3n85OasuPp2enywvKiugHiuneN9z49C0Bk1tlOPKCIfAlNcCpfSWtb1peQMtGssl042StallLxgi8iPyard3k9P15MvYrUOxPkYcfJpKx7jQCoQSYkZf_INepSkPs7uZko1mCpp2ptiOsjmVkn3fbXJYY77pGHTbGLpdDN0cQ7eNoVOz5vl-82TW3t0r7v4-Ay_3ABaLsc842FD-cEpAw-TWYr3jyjwaLn3-y-J_r_8G-Qqflg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1356917068</pqid></control><display><type>article</type><title>Supersolubilization and Amorphization of a Model Basic Drug, Haloperidol, by Interaction with Weak Acids</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Singh, Saumya ; Parikh, Tapan ; Sandhu, Harpreet K. ; Shah, Navnit H. ; Malick, A. Waseem ; Singhal, Dharmendra ; Serajuddin, Abu T. M.</creator><creatorcontrib>Singh, Saumya ; Parikh, Tapan ; Sandhu, Harpreet K. ; Shah, Navnit H. ; Malick, A. Waseem ; Singhal, Dharmendra ; Serajuddin, Abu T. M.</creatorcontrib><description>Purpose To present a novel approach of greatly enhancing aqueous solubility of a model weakly basic drug, haloperidol, by using weak acids that would not form salts with the drug and to attain physically stable form of amorphous drug by drying such aqueous solutions. Method Aqueous solubility of haloperidol in presence of increasing concentrations of four different weak organic acids (malic, tartaric, citric, fumaric) were determined. Several concentrated aqueous solutions with differing drug-to-acid molar ratios were dried in vacuum oven, and dried materials were characterized by DSC, powder XRD, dissolution testing, and stability study. Result Acids were selected such that they would not form salts with haloperidol. Haloperidol solubility increased greatly with increased concentrations of malic, tartaric and citric acids, reaching &gt;300 mg/g of solution. In contrast to the haloperidol HCl aqueous solubility of 4 mg/g, this may be called supersolubilization. Fumaric acid did not cause such solubilization as it had low water solubility. Dried solids formed dispersions of amorphous haloperidol in acids that were either amorphous or partially crystalline. Amorphous haloperidol was physically stable and had better dissolution rate than HCl salt. Conclusion A novel method of drug solubilization in aqueous media by acid–base interaction is presented. Physically stable amorphous systems of drugs may also be prepared by using this organic solvent-free approach.</description><identifier>ISSN: 0724-8741</identifier><identifier>EISSN: 1573-904X</identifier><identifier>DOI: 10.1007/s11095-013-0994-7</identifier><identifier>PMID: 23430485</identifier><identifier>CODEN: PHREEB</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Acids - chemistry ; Aqueous solutions ; Bioavailability ; Biochemistry ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedical Engineering and Bioengineering ; Biomedicine ; Dissolution ; Drug Stability ; Haloperidol - chemistry ; Hydrogen-Ion Concentration ; Medical Law ; Medical sciences ; Pharmaceutical sciences ; Pharmacology. Drug treatments ; Pharmacology/Toxicology ; Pharmacy ; Psychotropic drugs ; Research Paper ; Salts - chemistry ; Solubility ; Solutions - chemistry ; Water - chemistry</subject><ispartof>Pharmaceutical research, 2013-06, Vol.30 (6), p.1561-1573</ispartof><rights>Springer Science+Business Media New York 2013</rights><rights>2014 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c402t-d73ff3bdab8bab2b7d37b4da017e94a55ec18fb83608abc35196752b25f41aaa3</citedby><cites>FETCH-LOGICAL-c402t-d73ff3bdab8bab2b7d37b4da017e94a55ec18fb83608abc35196752b25f41aaa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11095-013-0994-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11095-013-0994-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=27406154$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23430485$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Singh, Saumya</creatorcontrib><creatorcontrib>Parikh, Tapan</creatorcontrib><creatorcontrib>Sandhu, Harpreet K.</creatorcontrib><creatorcontrib>Shah, Navnit H.</creatorcontrib><creatorcontrib>Malick, A. Waseem</creatorcontrib><creatorcontrib>Singhal, Dharmendra</creatorcontrib><creatorcontrib>Serajuddin, Abu T. M.</creatorcontrib><title>Supersolubilization and Amorphization of a Model Basic Drug, Haloperidol, by Interaction with Weak Acids</title><title>Pharmaceutical research</title><addtitle>Pharm Res</addtitle><addtitle>Pharm Res</addtitle><description>Purpose To present a novel approach of greatly enhancing aqueous solubility of a model weakly basic drug, haloperidol, by using weak acids that would not form salts with the drug and to attain physically stable form of amorphous drug by drying such aqueous solutions. Method Aqueous solubility of haloperidol in presence of increasing concentrations of four different weak organic acids (malic, tartaric, citric, fumaric) were determined. Several concentrated aqueous solutions with differing drug-to-acid molar ratios were dried in vacuum oven, and dried materials were characterized by DSC, powder XRD, dissolution testing, and stability study. Result Acids were selected such that they would not form salts with haloperidol. Haloperidol solubility increased greatly with increased concentrations of malic, tartaric and citric acids, reaching &gt;300 mg/g of solution. In contrast to the haloperidol HCl aqueous solubility of 4 mg/g, this may be called supersolubilization. Fumaric acid did not cause such solubilization as it had low water solubility. Dried solids formed dispersions of amorphous haloperidol in acids that were either amorphous or partially crystalline. Amorphous haloperidol was physically stable and had better dissolution rate than HCl salt. Conclusion A novel method of drug solubilization in aqueous media by acid–base interaction is presented. Physically stable amorphous systems of drugs may also be prepared by using this organic solvent-free approach.</description><subject>Acids - chemistry</subject><subject>Aqueous solutions</subject><subject>Bioavailability</subject><subject>Biochemistry</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedical Engineering and Bioengineering</subject><subject>Biomedicine</subject><subject>Dissolution</subject><subject>Drug Stability</subject><subject>Haloperidol - chemistry</subject><subject>Hydrogen-Ion Concentration</subject><subject>Medical Law</subject><subject>Medical sciences</subject><subject>Pharmaceutical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacy</subject><subject>Psychotropic drugs</subject><subject>Research Paper</subject><subject>Salts - chemistry</subject><subject>Solubility</subject><subject>Solutions - chemistry</subject><subject>Water - chemistry</subject><issn>0724-8741</issn><issn>1573-904X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kU9v1DAQxS1ERZfCB-CCLCEkDg2MYzuOj0uBtlIRB0Bwi8Z_0nXxxls7ESqfnmx3WxASp5Fmfm_maR4hzxi8ZgDqTWEMtKyA8Qq0FpV6QBZMKl5pEN8fkgWoWlStEuyQPC7lCgBapsUjclhzwUG0ckFWn6eNzyXFyYQYfuEY0kBxcHS5TnmzuuukniL9mJyP9C2WYOm7PF0e0zOMaZYHl-IxNTf0fBh9Rnsr-RnGFf3m8Qdd2uDKE3LQYyz-6b4eka8f3n85OasuPp2enywvKiugHiuneN9z49C0Bk1tlOPKCIfAlNcCpfSWtb1peQMtGssl042StallLxgi8iPyard3k9P15MvYrUOxPkYcfJpKx7jQCoQSYkZf_INepSkPs7uZko1mCpp2ptiOsjmVkn3fbXJYY77pGHTbGLpdDN0cQ7eNoVOz5vl-82TW3t0r7v4-Ay_3ABaLsc842FD-cEpAw-TWYr3jyjwaLn3-y-J_r_8G-Qqflg</recordid><startdate>20130601</startdate><enddate>20130601</enddate><creator>Singh, Saumya</creator><creator>Parikh, Tapan</creator><creator>Sandhu, Harpreet K.</creator><creator>Shah, Navnit H.</creator><creator>Malick, A. Waseem</creator><creator>Singhal, Dharmendra</creator><creator>Serajuddin, Abu T. M.</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20130601</creationdate><title>Supersolubilization and Amorphization of a Model Basic Drug, Haloperidol, by Interaction with Weak Acids</title><author>Singh, Saumya ; Parikh, Tapan ; Sandhu, Harpreet K. ; Shah, Navnit H. ; Malick, A. Waseem ; Singhal, Dharmendra ; Serajuddin, Abu T. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c402t-d73ff3bdab8bab2b7d37b4da017e94a55ec18fb83608abc35196752b25f41aaa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Acids - chemistry</topic><topic>Aqueous solutions</topic><topic>Bioavailability</topic><topic>Biochemistry</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedical Engineering and Bioengineering</topic><topic>Biomedicine</topic><topic>Dissolution</topic><topic>Drug Stability</topic><topic>Haloperidol - chemistry</topic><topic>Hydrogen-Ion Concentration</topic><topic>Medical Law</topic><topic>Medical sciences</topic><topic>Pharmaceutical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacy</topic><topic>Psychotropic drugs</topic><topic>Research Paper</topic><topic>Salts - chemistry</topic><topic>Solubility</topic><topic>Solutions - chemistry</topic><topic>Water - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Singh, Saumya</creatorcontrib><creatorcontrib>Parikh, Tapan</creatorcontrib><creatorcontrib>Sandhu, Harpreet K.</creatorcontrib><creatorcontrib>Shah, Navnit H.</creatorcontrib><creatorcontrib>Malick, A. Waseem</creatorcontrib><creatorcontrib>Singhal, Dharmendra</creatorcontrib><creatorcontrib>Serajuddin, Abu T. M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmaceutical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Singh, Saumya</au><au>Parikh, Tapan</au><au>Sandhu, Harpreet K.</au><au>Shah, Navnit H.</au><au>Malick, A. Waseem</au><au>Singhal, Dharmendra</au><au>Serajuddin, Abu T. M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Supersolubilization and Amorphization of a Model Basic Drug, Haloperidol, by Interaction with Weak Acids</atitle><jtitle>Pharmaceutical research</jtitle><stitle>Pharm Res</stitle><addtitle>Pharm Res</addtitle><date>2013-06-01</date><risdate>2013</risdate><volume>30</volume><issue>6</issue><spage>1561</spage><epage>1573</epage><pages>1561-1573</pages><issn>0724-8741</issn><eissn>1573-904X</eissn><coden>PHREEB</coden><abstract>Purpose To present a novel approach of greatly enhancing aqueous solubility of a model weakly basic drug, haloperidol, by using weak acids that would not form salts with the drug and to attain physically stable form of amorphous drug by drying such aqueous solutions. Method Aqueous solubility of haloperidol in presence of increasing concentrations of four different weak organic acids (malic, tartaric, citric, fumaric) were determined. Several concentrated aqueous solutions with differing drug-to-acid molar ratios were dried in vacuum oven, and dried materials were characterized by DSC, powder XRD, dissolution testing, and stability study. Result Acids were selected such that they would not form salts with haloperidol. Haloperidol solubility increased greatly with increased concentrations of malic, tartaric and citric acids, reaching &gt;300 mg/g of solution. In contrast to the haloperidol HCl aqueous solubility of 4 mg/g, this may be called supersolubilization. Fumaric acid did not cause such solubilization as it had low water solubility. Dried solids formed dispersions of amorphous haloperidol in acids that were either amorphous or partially crystalline. Amorphous haloperidol was physically stable and had better dissolution rate than HCl salt. Conclusion A novel method of drug solubilization in aqueous media by acid–base interaction is presented. Physically stable amorphous systems of drugs may also be prepared by using this organic solvent-free approach.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>23430485</pmid><doi>10.1007/s11095-013-0994-7</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0724-8741
ispartof Pharmaceutical research, 2013-06, Vol.30 (6), p.1561-1573
issn 0724-8741
1573-904X
language eng
recordid cdi_proquest_miscellaneous_1349704744
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Acids - chemistry
Aqueous solutions
Bioavailability
Biochemistry
Biological and medical sciences
Biomedical and Life Sciences
Biomedical Engineering and Bioengineering
Biomedicine
Dissolution
Drug Stability
Haloperidol - chemistry
Hydrogen-Ion Concentration
Medical Law
Medical sciences
Pharmaceutical sciences
Pharmacology. Drug treatments
Pharmacology/Toxicology
Pharmacy
Psychotropic drugs
Research Paper
Salts - chemistry
Solubility
Solutions - chemistry
Water - chemistry
title Supersolubilization and Amorphization of a Model Basic Drug, Haloperidol, by Interaction with Weak Acids
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T02%3A13%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Supersolubilization%20and%20Amorphization%20of%20a%20Model%20Basic%20Drug,%20Haloperidol,%20by%20Interaction%20with%20Weak%20Acids&rft.jtitle=Pharmaceutical%20research&rft.au=Singh,%20Saumya&rft.date=2013-06-01&rft.volume=30&rft.issue=6&rft.spage=1561&rft.epage=1573&rft.pages=1561-1573&rft.issn=0724-8741&rft.eissn=1573-904X&rft.coden=PHREEB&rft_id=info:doi/10.1007/s11095-013-0994-7&rft_dat=%3Cproquest_cross%3E2983909201%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1356917068&rft_id=info:pmid/23430485&rfr_iscdi=true